RxDoctor Payments DataLook up a doctor →

Tanvir Ahmad, MD

Internal Medicine · Plano, TXNPI 1649280777

Payments from drug & device makers

$3,524,383in general payments, 2019–2025

Across 188 payments — averaging $18,747 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.4M
  • AstraZeneca$99K
  • Sanofi US Services Inc.$27K
  • Pfizer$11K
  • Johnson & Johnson$158
  • Lilly USA, LLC$140
  • plus $1K from 26 others
$59,789in research payments, 2019–2025

Across 8 payments — averaging $7473.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$60K

What the payments were for

  • Travel & lodging$4,45962%
  • Food & beverage$2,69638%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,524,383 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$55,738
Medicare patients
215
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$54,125
OzempicSemaglutide43$42,631
JardianceEmpagliflozin24$33,108
FarxigaDapagliflozin Propanediol24$31,871
JanuviaSitagliptin Phosphate15$21,232
LinzessLinaclotide17$18,855
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$17,691
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$9,906
MounjaroTirzepatide11$9,457
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$4,812
Albuterol Sulfate HfaAlbuterol Sulfate70$2,527
Fluticasone Propionate118$2,421
SymbicortBudesonide/Formoterol Fumarate11$2,204
Nebivolol Hcl16$1,193
Omeprazole65$1,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11,139$54,12557 claims
Novo NordiskOzempic$70$42,63143 claims
AstraZenecaFarxiga, Symbicort$99,265$34,07435 claims
Boehringer IngelheimJardiance$35$33,10824 claims
MerckJanuvia$60$21,23215 claims
AbbVieLinzess$36$18,85517 claims
GSKTrelegy Ellipta$98$17,69113 claims
Lilly USA, LLCMounjaro$140$9,45711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →